Keywords: Diabetes; incretin; dipeptidyl peptidase; dpp (PubMed Search)
Posted: 12/3/2009 by Ellen Lemkin, MD, PharmD
Click here to contact Ellen Lemkin, MD, PharmD
NEW TREATMENT in diabetes
It was discovered that glucose given ORALLY caused more insulin release than glucose administered INTRAVENOUSLY. This led to the discovery of the incretin hormones, which are secreted by the gut (INtestinal SECRETion of INsulin), GIP and GLP-1.
The incretin-based therapies increase levels of GLP-1, either by providing an incretin mimetic (exenatide and liraglutide), or by inhibiting their breakdown by DPP-4 (sitagliptin, saxagliptin, vilagliptin)
Their administration results in:
STAY TUNED FOR DOSING AND ADVERSE EVENTS!
Barnett AH. New Treatment in type 2 Diabetes: A Focus on the Incretin-Based Therapies. Clinical Endocrinology Sep 2008;70(3):343-53.
Download the UMEM Pearls App!
Subscribe to daily UMEM Pearls (FREE!) via: